Eyecyte-RPE
Asset
Replaces damaged retinal pigment epithelial cells to support retinal function.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Not known
- 5
- Indications
- 755
- Trials
- 1
- Developer
Indications
5Age-related macular degeneration
Phase 1, Recruiting, NCT06394232, clinicaltrials.gov, 16 Oct 2026
Eye disease
Phase 1, Recruiting, NCT06394232, clinicaltrials.gov, 16 Oct 2026
Geographic atrophy
Phase 1, Recruiting, NCT06394232, clinicaltrials.gov, 16 Oct 2026
2 more
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials755
- Evidence for its targets1
- Competitors4
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.